首页> 外文OA文献 >Characterization of a New Humanized Anti-CD20 Monoclonal Antibody, IMMU-106, and Its Use in Combination with the Humanized Anti-CD22 Antibody, Epratuzumab, for the Therapy of Non-Hodgkin’s Lymphoma

【2h】

Characterization of a New Humanized Anti-CD20 Monoclonal Antibody, IMMU-106, and Its Use in Combination with the Humanized Anti-CD22 Antibody, Epratuzumab, for the Therapy of Non-Hodgkin’s Lymphoma

机译：新的人源化抗CD20单克隆抗体，IMPRU-106的表征及其与人源化抗CD22抗体，ePRATUZIMAB的用途，用于非霍奇金淋巴瘤的治疗

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Rhona Stein; Zhengxing Qu; Susan Chen; Adriane Rosario; Victoria Shi; Marianne Hayes; Ivan D. Horak; Hans J. Hansen; David M. Goldenberg;
展开▼
作者单位

展开▼
年度 2004
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. [J] . Strauss SJ, Morschhauser F, Rech J, Journal of Clinical Oncology . 2006,第24期

机译：在难治性或复发性非霍奇金淋巴瘤中，使用人源化抗CD22抗体，依普珠单抗联合利妥昔单抗进行免疫治疗的多中心II期试验。
2. The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma [J] . Christian Beth A., Poi Ming, Jones Jeffrey A., British Journal of Haematology . 2015,第5期

机译：人源化抗CD74抗体milatuzumab和人源化抗CD20抗体veltuzumab的组合显示了在复发性和难治性B细胞非霍奇金淋巴瘤患者中的活性
3. Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab). [J] . Leonard JohnP, Link BrianK Seminars in Oncology . 2002,第1Suppla2期

机译：用hLL2（抗CD22单克隆抗体埃普珠单抗）和Hu1D10（阿波珠单抗）对非霍奇金淋巴瘤进行免疫治疗。
4. Construction and characterization of a high-affinity humanized SM5-1 monoclonal antibody [C] . Bohua Li, Jianxin Dai, Yajun Guo, 第四届国际分子模拟与信息技术应用学术会议（The 4th International Conference of Molecular Simulations and Applied Informatics Technologies）论文集 . 2008

机译：高亲和力人源化SM5-1单克隆抗体的构建与表征
5. Humanization of a MUC16-Specific Monoclonal Antibody and Characterization of the MUC16 Epitope [D] . White, Brandy R. 2019

机译：MUC16特异性单克隆抗体的人源化和MUC16表位的表征
6. Correction: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus [O] . Thomas Dörner, Joerg Kaufmann, William A Wegener, 2008

机译：更正：依帕妥珠单抗（人源化抗CD22抗体）用于系统性红斑狼疮免疫治疗的初步临床试验
7. Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab. [O] . Lindén, Ola, Hindorf, Cecilia, Cavallin-Ståhl, Eva, 2005

机译：使用DOTa-缀合的90Y-放射性标记的人源化抗CD22单克隆抗体Epratuzumab在非霍奇金淋巴瘤中进行剂量分次放射免疫治疗。

Characterization of a New Humanized Anti-CD20 Monoclonal Antibody, IMMU-106, and Its Use in Combination with the Humanized Anti-CD22 Antibody, Epratuzumab, for the Therapy of Non-Hodgkin’s Lymphoma

著录项

相似文献

相关主题

期刊订阅